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symptoms of Incontinence (p≤0.04; Az=0.59, 0.61). Dmean 
predicted one single or two joint symptoms of Urgency 
(p=0.05; Az=0.57, 0.63). 
Conclusions: Based on a large number of atomized GU 
symptoms and a large number of patients treated at two 
centres, our results suggest that bladder maximum dose is 
particularly critical for patient-reported urinary incontinence 
and urgency after primary EBRT for localized prostate 
cancer. These findings together with a more comprehensive 
modelling approach have the potential to further improve our 
understanding of the complex dose-response of the GU tract. 
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Purpose/Objective: The prolongation of the overall 
treatment time (OTT) has influence in the control probability 
for certain type of tumours [1,2]. We develop a program to 
register interruptions that occur during the treatments and a 
protocol to compensate them with the help of a database. In 
this work we show the main results of applying these 
procedures during 42 months. 
Materials and Methods: We use Microsoft Access 2007© 
software to create a database of the treated patient. The 
more important fields are: demographic data, the ICD code 
of the disease, number of fractions and the dose per fraction, 
starting treatment date, the date in which the treatment 
should finish and the real ending date. If an interruption 
occurs, we register: the reason, the starting date and the 
ending date of it. The treatments were classified in three 
growing categories of prioritising according to the need to 
manage interruptions, using the criteria of [3]. In our 
protocol we try to keep the OTT for category one and 
prostate cancer according to [2] with the use of 
compensatory measures, these are mainly: give two sessions 
in the same day or one fraction with an equivalent dose of 
two fractions. The category two is compensated with 
increased total dose. We made a general analysis of the 
results of the interruptions management with the protocol 
described previously. In addition we categorized the 
treatments by their duration (CD): [0-10], [11-15], [16-28] 
and [29-40] treatment days and we obtained the average 
prolongation days (APD). Finally we studied the benefits of 
applying this protocol to different tumor sites: head and neck 
(HN), lung, cervix and breast (local control rate), and 
prostate (biochemical failure) using the data of [1] and [2]. 
Results: We analyzed 1893 treatments, 82.3% suffered an 
interruption with APD = 4.58, (4.37, 4.79) days, CI(95%). 31% 
of the interruptions had some kind of compensatory measure. 
The upper panel of the figure shows the APD for each one of 
the CD categories, the x-axis represents the treatment days 
median value of the category. The graphic shows a linear 
behavior with the total treatment days. This fact, and the 
high percentage of treatments that are interrupted, make 
necessary to take preventive actions for category 1 cases. 
The table show the absolute increase in TCP for each tumor 
site if we only include the compensatory measure to keep the 
OTT, column 1, and the column 2 is the result including all 
compensatory measures. In parentheses is the quantile of 
patients who have a benefit bigger than 4%. The HN and 
prostate treatments have a high APD because their highest 
duration (upper panel of figure), therefore the protocol pays 
special attention to these pathologies and the benefits are 
greater. The contrary occurs to breast cancer. The lower 
panel of the figure shows the histogram of the benefit in 
local control rate for HN patients.  
 
 
 
Conclusions: A compensatory measures program 
implementation improves the output of the treatments, 
especially in the HN. 
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